340B Gets Rebate Remix: HHS Pilots Price Switcheroo
Published Date: 8/3/2026
Notice
Summary
The U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), Office of Pharmacy Affairs (OPA), which administers the 340B Drug Pricing Program (340B Program), is issuing this Notice to announce the availability of a revised 340B Rebate Model Pilot Program (Pilot). The Pilot provides a rebate mechanism through which qualifying drug manufacturers may effectuate the 340B ceiling price for certain drugs sold to covered entities. Consistent with HRSA's longstanding statutory authority, rebates will be used instead of upfront discounts. HRSA issued a Request for Information (RFI) \1\ to gather input from interested parties regarding the potential use of rebates to effectuate the ceiling price under the 340B Program, including the standards and procedures that should govern the approval of manufacturer rebate plans and the impacts on all stakeholders. After carefully considering all comments from interested parties and different policy alternatives, HRSA is announcing this Pilot, which will implement a rebate approach for a limited set of drugs, and which builds on established and successful rebate programs. ---------------------------------------------------------------------------
Analyzed Economic Effects
5 provisions identified: 3 benefits, 1 costs, 1 mixed.
Rebates Used Instead of Upfront Discounts
HRSA is launching a revised 340B Rebate Model Pilot that lets qualifying drug manufacturers use rebates (instead of upfront discounts) to effectuate the 340B ceiling price for certain drugs sold to covered entities. The Pilot will apply to a limited set of drugs and builds on existing rebate programs used elsewhere in the drug system.
Pilot Targets Duplicate Discount Prevention
HRSA says the Pilot uses a rebate approach to help prevent duplicate discounts across federal pricing programs (including interactions with Medicaid and the Medicare Drug Price Negotiation Program). The agency frames the Pilot as a tool to improve program integrity and coordination across pricing programs.
Covered Entities May Face Cash-Flow Burdens
Covered entities (including Critical Access Hospitals, rural hospitals, FQHCs, and larger health systems) told HRSA that a rebate model could increase cash-flow and liquidity concerns, add administrative burden, and raise patient access worries. HRSA acknowledges these concerns and says it included implementation features to limit disruption.
Manufacturer Application Deadline Set
Manufacturers that want to participate must submit plans to [email protected] by August 24, 2026. Approved participation is tied to an effective date of January 1, 2027 for selected drugs covering initial price applicability year 2026 and 2027 during their price applicability periods.
HHS Must Pre-approve Rebate Models
HRSA states manufacturers may not unilaterally shift from upfront discounts to a rebate structure and that Secretarial pre-approval is required for rebate mechanisms. Courts have upheld HRSA's authority to require pre-approval.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20732, Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Data System for Organ Procurement and Transplantation Network, OMB No. 0906-0110-Revision
HRSA is asking for approval to keep collecting important data for the Organ Procurement and Transplantation Network, which helps manage organ donations and transplants across the U.S. They made some updates to the data they collect and want your feedback by November 9, 2026. This process keeps the system running smoothly without adding extra costs or delays.
2026-20731, Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; Applicant Organizational National Provider Identifiers and Centers for Medicare & Medicaid Services Certification Numbers Form
HRSA is introducing a new form to collect organization ID numbers (like National Provider Identifiers and Medicare Certification Numbers) from groups applying for funding. This helps make the application process smoother but doesn’t require organizations to get these numbers if they don’t already have them. Public comments on this new form are open until November 9, 2026, so now’s the time to speak up!
2026-20018, Recharter for the Council on Graduate Medical Education
The Council on Graduate Medical Education (COGME) has been officially rechartered as of September 30, 2026, to keep advising the government on doctor training and workforce needs. This affects medical schools, hospitals, and policymakers by continuing efforts to fix doctor shortages and improve training programs. No new funding changes are mentioned, but the council’s work will guide future health policies and education funding.
2026-19936, Autism Longitudinal Data Project and Linking the Boston Birth Cohort and Pregnancy to Early Life Longitudinal Data System and Community-Level Health Databases: A Longitudinal Cohort of Mother-Child Dyads
Johns Hopkins University is getting nearly $600,000 to finish a big project linking health data from moms and their kids to better understand autism and early life health. This funding keeps the project going through August 2027, helping researchers track health over time and improve care. If the money stops, the final phase can’t happen, slowing progress for families and communities counting on these insights.
2026-19886, AIM Incarcerated Women Resource Kit
In 2026, the government gave $750,000 to JSI Research & Training Institute to create a special resource kit for people who care for pregnant and new moms in jail. This kit will help healthcare and correctional staff provide better support for incarcerated women during pregnancy and after birth. The project runs from June 2026 to February 2027 and aims to improve care for a vulnerable group.
2026-19883, Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request; National Marrow Donor Program Patient Support Center Survey
The Health Resources and Services Administration (HRSA) is asking for public feedback on a survey that checks how happy patients and their families are with the National Marrow Donor Program’s support services. This survey helps improve care for people needing or having had a bone marrow transplant. Comments are open until October 29, 2026, and there’s no cost to participate—just your honest thoughts!
Previous / Next Documents
Previous: 2026-15631, Advisory Committee on the Medical Uses of Isotopes: Meeting Notice
The U.S. Nuclear Regulatory Commission (NRC) will convene a meeting of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on August 17, 2026, to discuss and provide recommendations from the subcommittee on Regulatory Guide 8.39, "Release of Patients Administered Radioactive Material" review of proposed patient release revisions in the Reforming and Modernizing the NRC's Radiation Protection Framework proposed rulemaking and draft revisions to Regulatory Guide 8.39. Meeting information, including a copy of the agenda and handouts, will be available on the ACMUI's Meetings and Related Documents web page at https://www.nrc.gov/reading-rm/doc- collections/acmui/meetings/2026 or by emailing Ms. Sarah Hoenig at the contact information below.
Next: 2026-15635, Angela Anatilde Baquero: Final Debarment Order
The Food and Drug Administration (FDA or the Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Angela Anatilde Baquero from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Angela Anatilde Baquero was convicted of a felony under Federal law for conduct relating to the development or approval, including the process for development or approval, of any drug product. Mrs. Baquero was given notice of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. As of May 6, 2026 (30 days after receipt of the notice), Mrs. Baquero has not responded. Mrs. Baquero's failure to respond and request a hearing constitutes a waiver of Mrs. Baquero's right to a hearing concerning this matter.